Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT) - Concepedia

Concepedia

Publication | Closed Access

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)

129

Citations

14

References

2018

Year

Mark Lebwohl, Andrew Blauvelt, C. Paul, Howard Sofen, Jolanta Węgłowska, Vincent Piguet, Daniel Burge, Robert Rolleri, Janice Drew, Luke Peterson,

Journal of the American Academy of Dermatology

References

	Year	Citations

Page 1